Originally published as JCO Early Release 10.1200/JCO.2007.12.0832 on July 30 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patt, D. A. Articles by Giordano, S. H. Search for Related Content PubMed PubMed Citation Articles by Patt, D. A. Articles by Giordano, S. H. Social Bookmarking                            What's this?

Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk

Debra A. Patt, Zhigang Duan, Shenying Fang, Gabriel N. Hortobagyi, Sharon H. Giordano

From the Departments of Medical Oncology and Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Sharon Giordano, MD, MPH, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 1354, Houston, TX 77030; e-mail: sgiordan{at}mdanderson.org

Purpose The purpose of this study was to determine the risk of developing acute myeloid leukemia (AML) after adjuvant chemotherapy for breast cancer in older women.

Patients and Methods Data from the Surveillance, Epidemiology, and End Results-Medicare linked database were used for women diagnosed with nonmetastatic breast cancer from 1992 to 2002. The primary end point was a claim with an inpatient or outpatient diagnosis of AML (International Classification of Diseases ninth revision, codes 205 to 208), comparing patients treated with and without adjuvant chemotherapy, and by differing chemotherapy regimens. The cumulative hazard of AML was estimated using the Kaplan-Meier method. Cox proportional hazards models were used to determine factors independently associated with the development of AML.

Results In this observational study, there were 64,715 patients: 10,130 received adjuvant chemotherapy and 54,585 did not. The median patient age was 75.6 years (range, 66 to 104 years). The mean follow-up was 54.8 months (range, 13 to 144 months). The absolute risk of developing AML at 10 years after any adjuvant chemotherapy for breast cancer was 1.8% versus 1.2% for women who had not received chemotherapy. The adjusted hazard ratio for AML with adjuvant chemotherapy versus none was 1.53 (95% CI, 1.14 to 2.06). Granulocyte colony-stimulating factor (G-CSF) within the first year of diagnosis did not convey a significantly increased risk of AML (hazard ratio, 1.14; 95% CI, 0.67 to 1.92).

Conclusion There is a small but real increase in AML after adjuvant chemotherapy for breast cancer in older women. This study may underestimate the true incidence because myelodysplastic syndrome cannot be identified through claims. G-CSF use within the first year of diagnosis does not convey an increased risk of AML in older women.

published online ahead of print at www.jco.org on July 30, 2007.

Supported by National Institutes of Health Grant No. 1K07 CA 109064-03 (S.H.G.) and by an American Society of Clinical Oncology 2006 Young Investigator Award (D.A.P.).

Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. B. Muss, D. A. Berry, C. T. Cirrincione, M. Theodoulou, A. M. Mauer, A. B. Kornblith, A. H. Partridge, L. G. Dressler, H. J. Cohen, H. P. Becker, et al. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer N. Engl. J. Med., May 14, 2009; 360(20): 2055 - 2065. [Abstract] [Full Text] [PDF]

				S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 J. Clin. Oncol., March 10, 2009; 27(8): 1177 - 1183. [Abstract] [Full Text] [PDF]

				L. Balducci Clinical Research in Older Cancer Patients Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 197 - 200. [Full Text] [PDF]

				L. Balducci, J. Tam-McDevitt, R. Hauser, and J. Simon Long Overdue: Phase II Studies in Older Cancer Patients: Where Does the FDA Stand? J. Clin. Oncol., March 10, 2008; 26(8): 1387 - 1388. [Full Text] [PDF]

				H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling In Reply Oncologist, December 1, 2007; 12(12): 1465 - 1466. [Full Text] [PDF]